使用GC-MS获得大皮的植物化学物质:抗氧化,抗炎和抗质作用在性结肠炎老鼠模型中
Duaa A Althumairy1, Rasha Abu-Khudir2, Afnan I Alandanoosi3
1Department of Biological Sciences, College of Science, King Faisal University, P.O. Box 380, Al-Ahsa 31982, Saudi Arabia.
Pharmaceuticals (Basel, Switzerland)
|July 30, 2025
概括
皮提取物 (GPE) 通过减少炎症和氧化应激,显示出治疗性结肠炎 (UC) 的潜力. 这项研究发现,GPE在老鼠模型中改善了肠道健康标志物,这表明IBD的自然治疗方法.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 自然产品化学 自然产品化学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病 (IBD),具有重大临床挑战.
- 研究自然化合物的治疗潜力在IBD是一个活跃的研究领域.
研究的目的:
- 为了评估大皮提取物 (GPE) 在酸 (AA) 诱导的大肠炎的老鼠模型中的保护作用.
- 确定GPE的植物化学成分,并将其与观察到的治疗效果相关联.
主要方法:
- 在AA诱导大肠炎前14天和14天后,小鼠被口服GPE (100mg/kg) 治疗.
- 气色谱-质谱法 (GC-MS) 用于分析GPE的化学成分.
- 测量了炎症,氧化应激和亡的生化标志物,以及抗氧化酶活动和细胞因子水平.
主要成果:
- GC-MS发现,GPE富含脂肪酸甲基,脂肪酸和维生素.
- 在大肠炎大鼠中,GPE治疗显著改善了体重和结肠长度.
- GPE降低了促炎性细胞因子 (IL-1,IL-6,IL-17,TNF-α,NF-κB) 和氧化应激标志物 (MPO,MDA) 的下调,同时降低了亡 (caspase-3).
- GPE增强了抗氧化酶活动 (CAT,SOD) 和增加了抗炎细胞因子IL-10水平.
结论:
- 大皮提取物在实验性结肠炎模型中显示出显著的抗炎,抗氧化和抗丧性质.
- 在GPE中发现的生物活性化合物可以协同作用,为性结肠炎提供治疗效益.
- GPE代表了一种有前途的天然治疗剂,用于治疗炎症性肠病.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
599
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
599
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
580
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
580
01:30Peptic Ulcer Disease I: Introduction
292
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
292
01:28Peptic Ulcer Disease II: Pathophysiology
856
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
856
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
694
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
694